New Laboratory Study Shows that NovaBay Pharmaceuticals’ Avenova Completely Inactivates the Bacterial Enzyme that Contributes to Blepharitis and Meibomian Gland Dysfunction
PHOENIX & EMERYVILLE, Calif.--(BUSINESS WIRE)--Phoenix Eye Care and NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that Dr. Arthur B. Epstein, Director of Clinical Research and head of the Dry Eye - Ocular Surface Disease Center at Phoenix Eye Care, discussed the benefits of NovaBay’s Avenova™ lid & lash cleanser at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The poster presentation was held today, May 6, from 11:00 a.m.–12:45 p.m. Centra
